InsiderSignal.AI

InsiderSignal.ai

CABA - Cabaletta Bio, Inc.

Insider Purchase by Tomasello Shawn (Dir)

3 Months
After Trade
Before Trade

Loading data...

Trade Summary

1 month ago, Tomasello Shawn, serving as Dir at Cabaletta Bio, Inc. (CABA), purchased 22,725 shares at $2.21 per share, for a total transaction value of $50,322.00. Following this transaction, Tomasello Shawn now holds 22,725 shares of CABA.

The trade was executed on Wednesday, January 21, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, January 21, 2026, meaning the disclosure happened on the same day as the trade.

Cabaletta Bio, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Tomasello Shawn

Dir

Shawn Tomasello is an independent Director at Cabaletta Bio, Inc. (CABA), appointed in July 2023, where she serves on the Compensation Committee and Science & Technology Committee.[[1]](https://fintool.com/app/research/companies/CABA/people/shawn-tomasello)[[2]](https://www.cabalettabio.com/news-media/press-releases/detail/92/cabaletta-bio-appoints-global-commercial-leader-shawn)[[3]](https://www.cabalettabio.com/about/board-of-directors) With over 35 years in the life sciences industry, she holds a B.S. in Marketing from the University of Cincinnati and an M.B.A. from Murray State University, and was age 66 as of April 2025.[[1]](https://fintool.com/app/research/companies/CABA/people/shawn-tomasello)[[2]](https://www.cabalettabio.com/news-media/press-releases/detail/92/cabaletta-bio-appoints-global-commercial-leader-shawn) Tomasello's career highlights include serving as Chief Commercial Officer (CCO) at Kite Pharma (2015–2018), leading the global launch of Yescarta, the first approved CAR-T therapy for non-Hodgkin lymphoma, through Gilead's acquisition; CCO at Pharmacyclics (2014–2015), managing Imbruvica prior to AbbVie's buyout; President of Americas Hematology & Oncology at Celgene with five product launches; and National Director of Hematology for Rituxan at Genentech over ~14 years.[[1]](https://fintool.com/app/research/companies/CABA/people/shawn-tomasello)[[2]](https://www.cabalettabio.com/news-media/press-releases/detail/92/cabaletta-bio-appoints-global-commercial-leader-shawn)[[3]](https://www.cabalettabio.com/about/board-of-directors) She has served on multiple public and private biotech boards, including current roles at 4D Molecular Therapeutics (FDMT) (since 2020) and Centrexion Therapeutics (since 2017), and a brief CEO stint at CoRegen, Inc. (Jan–Apr 2025).[[1]](https://fintool.com/app/research/companies/CABA/people/shawn-tomasello)[[4]](https://4dmoleculartherapeutics.com/team/shawn-tomasello-mba/)[[5]](https://centrexion.com/staff-member/shawn-tomasello/) Recently, as a CABA Director, she purchased 22,725 shares on January 21, 2026, at $2.21 per share.[[6]](https://www.marketbeat.com/instant-alerts/cabaletta-bio-nasdaqcaba-director-shawn-tomasello-acquires-22725-shares-2026-01-21/)[[8]](https://www.gurufocus.com/insider/28607/shawn-tomasello)

View full insider profile →

Trade Price

$2.21

Quantity

22,725

Total Value

$50,322.00

Shares Owned

22,725

Trade Date

Wednesday, January 21, 2026

32 days ago

SEC Filing Date

Wednesday, January 21, 2026

HEALTHCAREBIOTECHNOLOGY

About Cabaletta Bio, Inc.

Company Overview

No company information available
View news mentioning CABA

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/3306999

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime